Patents by Inventor Yasumichi Hitoshi
Yasumichi Hitoshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7482130Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: GrantFiled: July 27, 2006Date of Patent: January 27, 2009Assignee: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, Yonchu Jenkins
-
Publication number: 20090012045Abstract: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a RET kinase inhibitor. Cell proliferative disorders treatable by the methods include, thyroid tumors.Type: ApplicationFiled: June 26, 2008Publication date: January 8, 2009Applicant: RIGEL PHARMACEUTICALS, INC.Inventors: Yasumichi Hitoshi, Elliott Grossbard, Ankush Argade, Rajinder Singh
-
Patent number: 7413870Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: GrantFiled: December 21, 2001Date of Patent: August 19, 2008Assignee: Rigel Pharmaceuticals, IncorporatedInventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
-
Patent number: 7358040Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.Type: GrantFiled: December 21, 2001Date of Patent: April 15, 2008Assignee: Rigel Pharmaceuticals, IncorporatedInventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
-
Publication number: 20070128673Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: ApplicationFiled: July 27, 2006Publication date: June 7, 2007Applicant: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, Yonchu Jenkins
-
Publication number: 20060216299Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention binding partners of peptides that block the cell cycle. These binding partners are targets for drug discovery, e.g., for small molecule cancer therapeutics.Type: ApplicationFiled: October 30, 2003Publication date: September 28, 2006Applicant: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, David Anderson
-
Patent number: 7090990Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: GrantFiled: April 15, 2002Date of Patent: August 15, 2006Assignee: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, Yonchu Jenkins
-
Publication number: 20060147978Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.Type: ApplicationFiled: February 24, 2006Publication date: July 6, 2006Inventors: James Lorens, Todd Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Liao, Denise Pearsall, Annabelle Friera, Peter Chu
-
Patent number: 7056687Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.Type: GrantFiled: March 8, 2002Date of Patent: June 6, 2006Assignee: Rigel Pharmaceuticals, Inc.Inventors: James Lorens, Todd M. Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Charlene Liao, Denise Pearsall, Annabelle Freiro, Peter Chu
-
Publication number: 20060051755Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, which are involved in modulation of cell cycle arrest.Type: ApplicationFiled: April 15, 2003Publication date: March 9, 2006Applicant: RIGEL PHARMACEUTICALSInventors: Yasumichi Hitoshi, Yonchu Jenkins
-
Patent number: 7005254Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding LETM1 (“leucine zipper EF hand transmembrane receptor”), which is involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of LETM1 and LETM1 related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation.Type: GrantFiled: May 31, 2002Date of Patent: February 28, 2006Assignee: Rigel Pharmaceuticals, IncorporatedInventors: Susan Demo, Yasumichi Hitoshi, Denise Pearsall
-
Publication number: 20040126784Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding protein kinase C &zgr; (PKC-&zgr;), phospholipase C-&bgr;1 (PLC-&bgr;1), protein tyrosine kinase 2 (FAK), protein tyrosine kinase 2b (FAK2), casein kinase 2 (CK2), cMET tyrosine kinase (cMET), flap structure specific endonuclease 1 (FEN1), REV1 dCMP transferase (REV1), apurinic/apyrimidinic nuclease 1 (APE1), cyclin dependent kinase 3 (CDK3), PIM1 kinase (PIM1), cell division cycle 7 kinase (CDC7L1), cyclin dependent kinase 7 (CDK7), cytokine inducible kinase (CNK), potentially prenylated protein tyrosine phosphatase (PRL-3), serine threonine kinase 2 (STK2) or (NEK4), cyclin dependent serine threonine kinase (NKIAMRE), or histone acetylase (HBO1), which are involved in modulation of cell cycle arrest.Type: ApplicationFiled: July 14, 2003Publication date: July 1, 2004Applicant: Rigel Pharmaceuticals, IncorporatedInventors: Yasumichi Hitoshi, Yonchu Jenkins, Vadim Markovtsov
-
Patent number: 6727350Abstract: The present invention is directed to novel polypeptides such as the the Toso protein and related molecuels which have an inhibitory effect on TNF mediated apoptosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: August 17, 1998Date of Patent: April 27, 2004Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Garry P. Nolan, Yasumichi Hitoshi
-
Publication number: 20030194713Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: ApplicationFiled: April 15, 2002Publication date: October 16, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, Yonchu Jenkins
-
Publication number: 20030195138Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BAP-1, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of BAP-1; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: ApplicationFiled: April 15, 2002Publication date: October 16, 2003Applicant: Rigel PharmaceuticalsInventors: Yasumichi Hitoshi, Yonchu Jenkins
-
Publication number: 20030040001Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding LETM1 (“leucine zipper EF hand transmembrane receptor”), which is involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of LETM1 and LETM1 related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation.Type: ApplicationFiled: May 31, 2002Publication date: February 27, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Susan Demo, Yasumichi Hitoshi, Denise Pearsall
-
Publication number: 20030027167Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE 11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE 11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.Type: ApplicationFiled: December 21, 2001Publication date: February 6, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
-
Publication number: 20030027756Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: ApplicationFiled: December 21, 2001Publication date: February 6, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
-
Publication number: 20030022196Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.Type: ApplicationFiled: March 8, 2002Publication date: January 30, 2003Inventors: James Lorens, Todd M. Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Charlene Liao, Denise Pearsall, Annabelle Friera, Peter Chu
-
Publication number: 20020177565Abstract: The present invention is directed to novel polypeptides such as the the Toso protein and related molecuels which have an inhibitory effect on TNF mediated apoptosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologouspolypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: ApplicationFiled: August 17, 1998Publication date: November 28, 2002Inventors: GARRY P. NOLAN, YASUMICHI HITOSHI